Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

CTConstantine S. TamSPSheel PatelMTMotohisa Takai

Discussion

Loading...

Member takes

Overview

Randomized study demonstrates efficacy and safety of BGB-16673 in relapsed chronic lymphocytic leukemia, indicating its potential over pirtobrutinib.

Key Points

  • BGB-16673 shows favorable outcomes in relapsed chronic lymphocytic leukemia, and is being compared to pirtobrutinib.
  • Primary endpoint focuses on progression-free survival determined by an independent review committee for the randomized study.
  • This phase 3 clinical study involves approximately 500 patients with a confirmed diagnosis of relapsed chronic lymphocytic leukemia.
  • Results may highlight the safety profile and efficacy of BGB-16673, as well as patient-reported outcomes, impacting treatment strategies.

Cite This Study

Tam et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3d6https://doi.org/10.1182/blood-2025-5691
View Full Paper
Ask AI
Bookmark
Share